• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Uncategorized

 Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk
 0
By Nascent Biotech
In Uncategorized
Posted December 19, 2023

Nascent Biotech Completes Payment of Variable Convertible Note in Full to Eliminate Dilution Risk

NORTH PALM BEACH, FL / ACCESSWIRE / December 19, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial
 0
By Nascent Biotech
In Uncategorized
Posted January 25, 2023

Nascent Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial

NORTH PALM BEACH, FL / ACCESSWIRE / January 25, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech”, “Nascent”, or the “Company”), a clinical-stage [...]

READ MORE
 Daily Orange: Professor researches antibody as possible treatment for COVID-19
 0
By Nascent Biotech
In Uncategorized
Posted October 14, 2020

Daily Orange: Professor researches antibody as possible treatment for COVID-19

From Syracuse University’s Daily Orange website: A Syracuse University professor is conducting research into a possible treatment to combat coronavirus. Alison Patteson, an assistant [...]

READ MORE
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.